SeaSpine Holdings is leveraging Strategic Partnerships to Drive Double-Digit Growth in the Spinal Implants Market

10 Feb SeaSpine Holdings is leveraging Strategic Partnerships to Drive Double-Digit Growth in the Spinal Implants Market

Posted at 16:30h in Biotechnology, Technologies by admin 0 Comments

1 Like

SeaSpine Holdings Corporation (NASDAQ: SPNE), a Company leveraging technology to develop surgical solutions for spinal disorders, announced the signing of a strategic partnership with 7D Surgical Inc, a Toronto-based developer of advanced image guidance technologies and machine-vision-based registration algorithms. 7D Surgical’s proprietary Machine-vision Image Guided Surgery (MvIGS) platform will be used to develop SeaSpine-specific instrumentation, which can be used for spinal and cranial surgeries, in addition to integrating and co-marketing their product offerings. The integration will enable SeaSpine to offer customized, best-in-class navigational solution to its network of customers on a non-exclusive basis as per a Company statement.

The pioneering 7D Surgical MvIGS system utilizes proprietary machine-vision algorithms and camera-based technology to overcome the limitations offered by conventional surgical navigation systems. Most importantly its use of visible light instead of fluoroscopy eliminates exposure to intraoperative radiation, for the surgeon as well as the surgical team, enabling the surgeon to improve his efficiency and control the system from a sterile field.

Keith Valentine, SeaSpine President and Chief Executive Officer, commented

“We have been extremely impressed by 7D’s ability to improve surgical workflow and the timing of our collaboration is ideal. With over 12 product launches expected in 2020, including limited commercial launches of our initial 3D-printed offerings and full commercial launches of our foundational Mariner system in additional market segments, such as MIS and deformity, that give us access to over $2 billion in new market opportunities, the introduction of 7D’s best-in-class navigation system further enhances our ability to offer a complete, integrated and seamless procedural solution in spine. Equally important, by using visible light, rather than fluoroscopy, the 7D Surgical System does not expose operating room personnel to unnecessary, additional radiation.”

SeaSpine Holdings Corporation (NASDAQ: SPNE)

Market Cap: $288.39M; Current Share Price: 15.15 USD Chart
Data by YCharts

Industry
The increasing incidents of Spinal Cord Injuries (SCI) and the advancement of technology in the Spinal Injuries market will drive the growth in the Spinal Implants and Surgical devices market as per a report by Markets and Markets. The market is projected to reach $17.27 billion by 2021, growing at a CAGR of 5.3%. SCI’s alone cost an estimated $40.5 billion annually in terms of healthcare costs; about $158 billion is spent on home care and nursing home services combined, with friends or family members providing care that is valued at $306 billion annually.

According to a report by the National Spinal Cord Injury Statistical Center, the number of people living with SCI’s is estimated to be approximately 288,000 persons, with a range from 247,000 to 358,000 persons, with the annual incidence of spinal cord injury estimated to be between 54 cases per one million people in the United States, or about 17,700 new SCI cases each year.

The global spinal cord trauma market which was valued at $2.28 billion in 2017 is projected to reach $3.04 billion by 2025 with a CAGR of 3.7 percent according to a report by Persistent Market Research. The increasing incidences of spine related injuries owing to motor accident, workplace injuries, stroke and cancer related motor disability along with hyperextension of the spine and vertebral dislocation will spur the growth in the market.

Increasing regulatory support to reduce SCI’s coupled with scientific advancements in the market as well as stem cell research will help the market grow. However the economic burden of the disease and lack of insurance coverage is a major challenge for those suffering from SCI, making it difficult for them to seek and adapt technological advancements in the field.

Company
SeaSpine was created as a spin-off from a spinal implants and orthobiologics division into a spine company dedicated to creating innovative surgical solutions. The Company is committed to developing the most advanced spinal surgery solutions, by collaborating with leading surgeons, and leveraging its expertise in orthobiologics, interbody devices and modular spinal instrumentation systems.

The Company designs, develops and commercializes high-quality spine-fusion and orthobiologics products covering areas such as Throacolumbar solutions like Access Systems, Anterior/Lateral fixation, Tumor/ Trauma; Cervical solutions such as Anterior/Posterior fixation; orthobiologics such as allografts, graft delivery, synthetics and IsoTis Orthobiologics.

Image Source: Company

Furthermore, it offers procedures such as ACDF, ALIF, Corpectomy, Laminoplasty, MIS Decompression, LLIF, PLIF/TLIF, Posterior cervical fusion to name a few. The Company has an extensive intellectual property rights portfolio with patent protection for its products and services covering its Atoll system, Balboa Anterior Buttress Plate, BodyForm system, Manta Ray system, Steerable interbody system to name a few.

The Company offers three complimentary medical education programs to its partners including surgeons and the sales team under the name Coast, SeaSpine Institute and PIER (Physician Interaction and Education Resources). SeaSpine derives 90 percent of its revenues from the U.S Market and enjoys the number 2 position in demineralized bone matrix (DBM). In addition it has a robust surgeon collaboration and distribution network.

Image Source: Company

Risk Assessment

SeaSpine is targeting an addressable market of close to $7.1 billion, including a $5.4 B cervical and thoracolumbar interbody and fixation device market and a $1.7B bone graft substitute growth factors and cellular grafts market. The spinal implants market specifically offers high margins, and will see new product launches in 2020, helping the Company to improve its growth and revenue margins.

The Company is building strategic partnerships that offer complementary technologies, which will help differentiate its offerings from the competitor and also provide entry into diversified segments of the industry. In September 2019, the Company signed an exclusive development and licensing agreement with restor3d, Inc., a company specializing in 3D-printed implants, with plans to develop 3D-printed interbody devices. The first 3D-printed interbody device to be developed under the agreement is likely to be commercialized in 2H, 2020.

The Company has a strong distribution network, with nearly 58 percent of its U.S sales being contributed by its core distributors, who exclusively stock SeaSpine spinal implants and Orthobiologics products. The Company is also forging strong surgeon collaboration through initiatives such as its surgeon education programs, which will not only help it gain visibility and recall but also market share.

As per its full year 2019 financial results, the Company reported an impressive 20 percent growth in the U.S spinal implants portfolio, SeaSpine intends to maintain the momentum with the launch of new products in the spinal category in 2020, with potential to continue the double–digit revenue growth.

The Company uses complimentary educational programs designed to deliver value to its distributors and surgeons by focussing on areas such as market development, surgeon education and sales training.

SeaSpine recently made a public offering of 6.8 million common shares priced at $12.50 per share amounting to total gross proceeds of nearly $85 million. The Company currently has zero debt and intends to use these proceeds for its working capital requirements and general corporate purposes. As of December 31, 2019, the Company had cash and cash equivalents of $20.2 million. It also has a $30 million credit facility, which can be extended to up to $40 million.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Click here to please visit our detailed disclosure

Source

https://finance.yahoo.com/news/seaspine-7d-surgical-announce-entry-170010908.html

https://www.marketsandmarkets.com/PressReleases/spine-surgery-devices.asp

https://www.seaspine.com/company/our-story/

https://www.nscisc.uab.edu/Public/Facts%20and%20Figures%20-%202018.pdf

http://investor.seaspine.com/static-files/7609d152-dc96-452a-b20b-970ff65b0629 http://investor.seaspine.com/static-files/7609d152-dc96-452a-b20b-970ff65b0629

http://investor.seaspine.com/press-releases?a42c08eb_year%5Bvalue%5D=2019&op=Filter&a42c08eb_widget_id=a42c08eb&form_build_id=form-S6llClYUV3yJerx6VfF7EaB20O0dsG0SWuS4y5L5DC0&form_id=widget_form_base